CAR-T 细胞治疗八十岁以上 B 细胞淋巴瘤患者：一项美国真实世界多中心协作研究

Older patients with lymphoma are typically underrepresented in clinical trials with chimeric antigen receptor T cell (CAR T) therapy. In this multicenter, observational study we aimed to assess the safety and efficacy of standard CD19 CAR T in patients 80 years of age or older. At total of 88 patients, median age 82 (range, 80-89) years, were included. Diffuse large B cell lymphoma (DLBCL) (N = 60, 68. 2%) represented the most common histology.

Patients were treated mostly with axicabtagene ciloleucel (N = 41, 46. 6%) followed by lisocabtagene maraleucel (N = 25, 28. 4%). Cytokine release syndrome (CRS) (any grade) was seen in 68 (77. 3%) and 51 (58%) developed immune effector cell-associated neurotoxicity syndrome (ICANS). Incidence of grade 3-4 CRS and ICANS were 7. 4% and 31. 4%, respectively. For patients with DLBCL/tFL, the 1-year NRM, relapse, PFS, and OS were 11. 6%, 40. 8%, 47. 6%, and 61. 2%, respectively.

We conclude that CAR T is feasible and effective in patients 80 years or older with B cell lymphomas. These patients must be provided the opportunity to be evaluated for this curative approach.